InPharmd
YC W21Atlanta, US · Founded 2018 · 16 employees · 3 known investors
InPharmD is a medical literature research platform that analyzes published studies to answer clinical pharmacology questions, specifically focused on adverse drug reactions and medication safety.
AI & Machine LearningDigital HealthHealthtechArtificial IntelligenceB2BTelemedicinein /inpharmd@inpharmdycombinator.com ↗
Founders & leadership· Y Combinator alumni (W21)
AA
Ashish Advaniin𝕏Founder
TR
Tulasee Rao Chinthain𝕏Founder
Investors · 3
In the news
- Lowenstein Represents 645 Ventures as Lead Investor in the Series Seed Fund Raise for AI-Based Drug Information Service InpharmD | Lowenstein Sandler LLPlowenstein.com · 2023
- Exclusive: InpharmD seeds $6M for on-demand drug infoinpharmd.com · 2023
- InpharmD Funding | $2-5M Revenue | Complete Analysis | Extruct AIextruct.ai · 2023
- Atlanta-based InpharmD Secures $6.05M in Fundingstartuprise.io · 2023
- InpharmD Raises $6.05M in Fundingfinsmes.com · 2023
- Decoding InpharmD - Revolutionizing Drug Information with AIinpharmd.com · 2023
- Qlarant Capital Becomes Investor in InpharmD™globenewswire.com · 2023